Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients - a nationwide and longitudinal study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study analyzed treatment patterns and survival for advanced non-squamous NSCLC patients in Norway. Targeted therapies showed improved overall survival despite shorter time on treatment compared to clinical trials.
Area Of Science
- Oncology
- Thoracic Oncology
- Genomics in Cancer Therapy
Background
- Advanced non-squamous non-small cell lung cancer (NSCLC) with specific genetic alterations (EGFR+, ALK+, ROS1+) requires tailored treatment strategies.
- Understanding real-world treatment patterns, time on treatment (ToT), and overall survival (OS) is crucial for optimizing care in Norway.
Purpose Of The Study
- To describe treatment patterns, ToT, and OS for patients with advanced non-squamous, EGFR+, ALK+, and ROS1+ NSCLC in Norway.
- To evaluate survival trends in relation to diagnosis period and targeted therapy utilization.
Main Methods
- Retrospective analysis of 5,279 patients diagnosed with advanced non-squamous NSCLC between 2015-2022.
- Data extracted from the Cancer Registry of Norway, Norwegian Patient Registry, and Norwegian Prescribed Drug Registry.
- ToT and OS calculated from treatment initiation/collection and diagnosis date, respectively.
Main Results
- High rates of systemic treatment initiation within three months for EGFR+ (75%), ALK+ (88%), and ROS1+ (58%) patients.
- Median first-line ToT varied by drug: Osimertinib (11 months) for EGFR+; Alectinib (20 months) for ALK+; Crizotinib (5 months) for ROS1+.
- Patients diagnosed in 2020-2022 showed significantly higher unadjusted median OS (23 months) compared to those diagnosed in 2015-2019 (19 months).
Conclusions
- While time on treatment for targeted therapies was shorter than progression-free survival in clinical trials, patients benefited from improved overall survival.
- Real-world data indicate a positive survival trend for patients with targetable genomic alterations in NSCLC during the study period.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...